The dilemma of MDR-TB in the global era

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 11, 1998, Pages 869-876

  Farmer, Paul ^a   Bayona, J ^a   Becerra, M ^a   Furin, J ^a   Henry, C ^a   Hiatt, H ^a   Kim, J Y ^a   Mitnick, C ^a   Nardell, E ^a   Shin, S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

EPIDEMIC; HUMAN; MULTIDRUG RESISTANCE; POVERTY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

DEVELOPING COUNTRIES; HEALTH PLANNING; HUMANS; MORALS; POVERTY; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 7844231314     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Iseman M. Tailoring a time-bomb. Am Rev Respir Dis 1985; 132: 735.
2. Hopewell P C, Sanchcz-Hernandez M, Baron R B, Ganter B. Operational evaluation of treatment for tuberculosis. Results of a 'standard' 12-month regimen in Peru. Am Rev Respir Dis 1984; 129: 439-443.
3. Hopewell P C, Ganter B, Baron R B, Sanchez-Hernandez M. Operational evaluation of treatment for tuberculosis. Results of 8- and 12-month regimens in Peru. Am Rev Respir Dis 1985; 132: 737-741.
4. Black W, Ganter B, Grzybowski S, Sanchez-Hernandez M, Hopewell P. Prevalence of initial bacillary resistance to antituber- culous drugs in Peruvian patients with newly-discovered tuberculosis [abstract]. Am Rev Respir Dis 1985; 131 (Suppl): A225.
5. Ministerio de Salud. Programa National de Control de la Tuberculosis en el Perú Año 1994. Lima, Perú: Ministerio de Salud, 1995.
6. Farmer P E, Bayona J, Becerra M, Shin S, Nunez C, Nardell E, and the International Working Group on Multidrug-Resistant Tuberculosis. The emergence of MDR-TB in urban Peru: a population-based study using conventional, molecular, and ethnographic methods. Poster Presented at the Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease, Paris, October 1-4, 1997.
7. Gilman R H. Lecture delivered at IX National Congress of Internal Medicine, Lima, Peru. 1996.
8. Laszlo A, de Kantor I N. A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ 1994; 72(4): 603-610.
9. Ministerio de Salud, Programa Nacional de Control de Enfermedades Transmisibles - Control de la Tuberculosis. Vigilancia de la resistencia a los medicamentos antituberculosos en el Perú, 1995-1996. Lima, Perú: Ministerio de Salud, 1996.
10. World Health Organization. TB Treatment Observer, March 24, 1997.
11. World Health Organization. WHO Report on the Tuberculosis Epidemic. Geneva; WHO, 1997.
12. Cohn D L, Bustreo F, Raviglione M C. Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin Infect Dis 1997; 24 (Suppl 1): S121-S130.
13. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994-1997. Geneva; WHO, 1997.
14. Khornenko A, and Médecins sans Frontières, cited in Reyes H, Coninx R. Pitfalls of tuberculosis programmes in prisons. Br Med J 1997; 315: 1447-1450.
15. Farmer P E, Bayona J, Becerra M, et al. Poverty, Inequality, and Drug Resistance: Meeting Community Needs. Proceedings of the International Union Against Tuberculosis and Lung Disease North American Region Conference 1997; 88-102.
16. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
17. Manalo F, Tan F, Sbarbaro J A, Iseman M D. Community-based short course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990; 142: 1301-1305.
18. Coates A R M, Mitchison D A. The role of sensitivity tests in short course chemotherapy. Bull Int Union Tuberc 1983; 58: 110-114.
19. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
20. Abderrahim K, Chaulet P, Oussedik N, Amrane R, Hassen C S, Mercer N. Practical results of standard first-line treatment in pulmonary tuberculosis: influence of primary resistance. Bull Int Union Tuberc 1976; 51: 359-366.
21. Zhang L X, Kan G Q, Tu D H, Li J S, Lui X X. Trend of initial drug resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis programme in Beijing. Tubercle Lung Dis 1995; 76: 100-103.
22. Kim S J, Bai S H, Hong Y P. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997; 1: 302-308.
23. Frieden T R, Fujiwara P, Washko R, Hamburg M. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
24. Blower S M, Small P M, Hopewell P C. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996; 273: 497-500.
25. Packard R. White plague, black labor: tuberculosis and the political economy of health and disease in South Africa. Berkeley, CA; University of California Press, 1989.
26. McKenna M T, McCray E, Onorato I. The epidemiology of tuberculosis among foreign born persons in the United States, 1986-1993. N Engl J Med 1995; 332: 1071-1076.
27. Bifani P, Pjikaytis B, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275: 452-457.
28. Zuber P L, McKenna M T, Binkin N J, Onorato I M, Castro K G. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997; 278: 304-330.
29. Garrett L. 'TB surge in former East Bloc'. Newsday, March 25, 1998, p A21.
30. Institute of Medicine. America's Vital Interest in Global Health. Washington, DC; National Academy Press, 1997.
31. Economies Intelligence Unit. First quarter 1997 report. The Economist, 1997.
32. Reichman L B. Tuberculous elimination - what's to stop us? Int J Tuberc Lung Dis 1997; 1: 3-11.
33. Murray C J L, Lopez A D, eds. The global burden of disease. Cambridge; Harvard University Press, 1996.
34. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
35. Wilson M E, Levins R, Spielman A, eds. Disease in evolution: global changes and emergence of infectious diseases. Vol. 740. New York; New York Academy of Sciences, 1994.
36. Winker M A, ed. A global theme issue: bibliography of references, Emerging Infect Dis 1996; 2: 365-372.
37. Farmer P E, Kim J Y. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus". Brit Med J 1998; 317: 671-674.